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Chansu is one of themost widely used traditional Chinesemedicines inChina, Japan, and other Southeast Asian countries primarily
for antipain, anti-inflammation, and recently anticancer. Over 10 recipes and remedies contained Chansu, which are easily available
in pharmacies and hospitals, but themechanisms of actionwere not clearly articulated. In the present study, Cinobufagin (CBF), the
major compound of Chansu, was employed as a surrogatemarker to determine its ability in inducing cancer cell death. As expected,
CBF has significant cancer-killing capacity for a range of cancers, but such ability differs markedly. Colon and prostate cancers are
more sensitive than skin and lung cancers. Interestingly, cancer cells die through apoptotic pathway either being biphasic caspase-
3-dependent (HCT116) or independent (HT29). Multipathway analysis reveals that CBF-induced apoptosis is likely modulated by
the hypoxia-inducing factor-1 alpha subunit (HIF-1𝛼) as its inhibition was evident in vitro and in vivo. Taken together, these results
demonstrate that CBF is a potent apoptotic inducer with potential for further development as a novel and effective anticancer agent
for a range of cancers, especially colon cancer.
1. Introduction
In the last decade, considerable efforts have focused on
improving cancer chemotherapeutics because conventional
therapies fail to manage cancer effectively without causing
significant side effects on patients [1–5]. There is a notion
that a “chemotherapy efficacy plateau” has been reached [5,
6]. Since traditional herbal medicines have been used suc-
cessfully for hundreds of years, potential novel anticancer
compounds are being eagerly sought from them. Extensive
research on examining the ability of natural compounds in
inducing apoptosis, and with it the mechanisms of action has
been reported [7–10].
Traditional Chinese medicine Chansu is a dried product
of glandular secretion from the Asiatic toad (Bufo gargari-
zan). It has been used for centuries in various prescriptions,
recipes, and ready-available remedies, such as Liushenwan
(anti-inflammation), Shexiangbaoxinwan (antiarrhythmia),
and Niuhuangxiaoyanwan (anti-inflammation and anaesthe-
sia) in China, Japan, and other Southeast Asian countries [11,
12]. Recently, Chansu has been used as significant anticancer
agents, amending the life quality of cancer patients [13].
Major components in Chansu include a group of bufa-
dienolides, including Cinobufagin (CBF), Bufalin, and Resi-
bufogenin [14]. CBF accounts up to six to seven percent of
Chansu. Limited research on Chansu and its components has
shown proapoptotic functions [14–17] and an inhibitive effect
on a wide range of cancer cells [18–21]. Kamano et al. [22]
reported that CBF has a potent inhibitory capacity against
primary liver carcinoma cells. CBF has also been found to
belong to the family of cardiac glycosides (CGs) and inhibit
Na+/K+-ATPases activity [23], which emerged recently as
novel drugs in prevention of cancer proliferation without
serious side effects [24].
In this study we aimed to explore the capacity of CBF
in inhibiting cancer cell proliferation and the mechanisms of
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such an effect. The understanding of the intracellular activi-
ties of CBF would assist us to develop the natural compound
into a novel agent for cancer therapy.
2. Experimental
2.1. HumanCell Lines andCulture Conditions. Human cancer
cell line HCT116 (colon), HT29 (colon), A431 (skin), PC3
(prostate), A549 (lung), and MCF-7 (breast) were purchased
from American Tissue Culture Collection. Human lung
cancer cell line Spc-A
1
was purchased from Cell Bank of
Chinese Academy of Sciences. All the cancer cell lines were
cultured in Dulbecco’s modified essential medium (Gibco,
life technologies, VIC, Australia) supplemented with 10%
foetal bovine serum (HyClone, Thermo Fisher Scientific,
VIC, Australia), 100U/mL penicillin (Sigma, Sigma-Aldrich,
NSW, Australia), 100𝜇g/mL streptomycin (Sigma), 110mg/L
sodium pyruvate (Gibco), and 25mM HEPES (Gibco), in
an atmosphere of 5% CO
2
and 95% air at 37∘C. To culture
cells under hypoxic conditions, flasks containing cell lines
were placed in a GasPak EZ pouch (BD, MD, USA) or were
exposed to 100 𝜇MCoCl
2
(Sigma).
2.2. Cytotoxicity Assays. Cytotoxicity of CBF in all cell
lines was studied by using 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) assays (Molecular
Probes, life technologies, OR, USA). After the 24 hours
starvation in serum-free culture, cells (1 × 104 cells per a
96 well) were exposed to CBF and/or N-Acetyl-L-cysteine
(NAC) treatment for another 24 or 48 hours, and then MTT
reagent was added following the manufacturer’s instructions.
The absorbance was read at 570 nm and EC
50
values were
calculated by Prism 5 (GraphPad Software, CA, USA). CBF
and NAC were purchased from Sigma and dissolved in
dimethyl sulfoxide.
2.3. Detection of Annexin V/Propidium Iodide (PI) Apoptosis.
HCT116 and HT29 cells were treated with 1 𝜇M CBF or
0 𝜇M of CBF as a negative control for 24 hours. The cells
were harvested and stained with an AlexaFluor 488 Annexin
V/Dead cell apoptosis kit (Molecular Probes). Experiments
were performed according to themanufacturer’s instructions.
2.4. Analysis of Mitochondrial Potential Changes. HCT116
and HT29 cells (1 × 104 cells per a black 𝜇Clear 96 well
(Greiner Bio-One, Frickenhausen, Germany)) were treated
with 1 or 0𝜇M of CBF. 5,5󸀠,6,6󸀠-tetrachloro-1,1󸀠,3,3󸀠-tetraeth-
ylbenzimidazolocar-bocyanine iodide (JC-1) dye (Sigma-
Aldrich, MO, USA) was added to the cells at 3, 6, 9, 12, 15, 18,
24, and 48 hours. The experiment was carried out following
the protocols provided by the manufacturer. At different
time points, both red fluorescence and green fluorescence
were recorded using POLARstarOmega (BMGLabtech, VIC,
Australia).
2.5. Multipathway Reporter Assays. This multipathway activ-
ity assay was performed using Cignal Finder Toxicity 10-
Pathway Reporter Arrays (SABiosciences, Qiagen, VIC, Aus-
tralia) according to themanufacturer’s instructions. Reporter
and control DNA constructs of 10 selected transcription
factors were transfected into HCT116 cells (3 × 104 cells per
a 96 well) using Lipofectamine LTX reagent (Invitrogen, life
technologies, VIC, Australia). Twenty-four hours later, cells
were treated with 1 𝜇MCBF for 9 hours.The luciferase assays
were then carried out by using Dual-Glo luciferase assay
systems (Promega, WI, USA).
2.6. Immunofluorescent Staining. For in vitro experiments,
cells were grown on sterile 15mm coverslips (1.5 × 105
cells/coverslip/well) in a 24-well plate. After CBF treatment,
cells were blocked in block buffer (3% normal goat serum
and 0.5% BSA in 0.01M PBS) for 30min. For in vivo, fixed
tissues were blocked in the same block buffer. Cells or tissues
were sequentially incubated with corresponding primary
antibodies against active caspase-3 (1 : 100; Abcam, Sapphire
Bioscience, NSW, Australia), AIF (1 : 100; Cell Signalling,
MA, USA), or HIF-1𝛼 (1 : 100; Novus, CO, USA), followed
by incubation with a secondary antibody FITC or Texas
Red-conjugated goat anti-rabbit IgG (1 : 2000; Abcam). The
coverslips or tissues were then counterstained with DAPI
(Molecular Probes) and treated with ProLong Gold antifade
reagent (Molecular Probes). After 24 hours, fluorescence
images were visualised using confocal microscopy (FV1000,
Olympus, QLD, Australia).
2.7. Caspase-3/7 Activity Assays. Cells (1 × 104 cells per a
white 𝜇Clear 96 well (Greiner Bio-One)) were exposed to
CBF for 24 hours. The activity of caspase-3 was evaluated
using Caspase-Glo 3/7 assay systems (Promega) according
to the manufacturer’s instructions. Luciferase intensity was
measured by POLARstar Omega at 4, 8, 12, and 24 hours after
CBF addition.
2.8. Real-Time RT-PCR. Total RNA was isolated from
HCT116 and HT29 cells after 12 and 24 hours CBF treatment
using Purelink RNA Mini Kit (Ambion, life technologies,
CA, USA). RNAs in mouse tissues were initially stabilised
by immersing in RNAlater (Ambion) and extracted using
Trizol reagent (Ambion). To synthesize first-strand cDNA,
SuperScript III Reverse Transcriptase (Invitrogen) was used
according to the manufacturer’s instructions. Real-time PCR
was carried out in a 20 𝜇L of reaction solution, with Express
SYBR GreenER qPCR SuperMix (Invitrogen). No genomic
DNA contamination or pseudogenes were detected. Primers
used in real-time PCR were Human AIF (Forward: 5󸀠-CTG
AAA GAC GGC AGG AAG GTA G-3󸀠, Reverse: 5󸀠-CTC
CAG CCA ATC TTC CAC TCA C-3󸀠). Human caspase-
3 (Forward: 5󸀠-GTT TGT GTG CTT CTG AGC CAT G-
3󸀠, Reverse: 5󸀠-CCA CTG TCT GTC TCA ATG CCA C-
3󸀠). Human HIF-1𝛼 (Forward: 5󸀠-AAG GTA TTG CAC TGC
ACA GGC-3󸀠, Reverse: 5󸀠-CAG CAC CAA GCA GGT CAT
AGG-3󸀠). Human GAPDH (Forward: 5󸀠-GTC TCC TCT
GACTTCAACAGCG-3󸀠, Reverse: 5󸀠-ACCACCCTGTTG
CTG TAG CCA A-3󸀠).
2.9. Western Blotting. CBF-treated cells were scraped and
lysed in cold lysis buffer, consisting of 25mM of Tris (pH7.4),
125mM of NaCl, 2.5mM of EDTA, 25mM of NaF, 0.5mM
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Na
3
VO
4
, 0.5% Nonidet-P40, and 0.01% NaN
3
, supplemented
with 1mM PMSF (Sigma) and protease inhibitor cocktail
(Sigma). Mouse tissues (<125mm3) were initially ground by
mortar and pestle, followed by the immersion in lysis buffer.
After SDS-PAGE and PVDF transfer, protein samples were
incubated with primary antibodies against AIF (1 : 1000),
active caspase-3 (1 : 1000), HIF-1𝛼 (1 : 500), or 𝛼-Tubulin load-
ing control (1 : 2000; Abcam) overnight at 4∘C, followed by
incubating with horseradish peroxidise-conjugated goat anti-
mouse or anti-rabbit (1 : 7500; Abcam) antibodies. SuperSig-
nal chemiluminescent substrate (Pierce, IL, USA) was finally
added, and the chemiluminescence was visualised using a
VersaDoc 4000MP system (Bio-Rad, CA, USA).
2.10. Transient Transfection Assays. Vectors encoding full-
length human HIF-1𝛼 and pEGFP-C1 (Clontech, CA, USA)
were kindly provided by Dr. Zhou Wang and Associate Prof.
Steve Ralph, respectively. The sequence of full-length HIF-1𝛼
was amplified by PCR and inserted in a pEGFP-C1 vector,
which generated pGFP-HIF-1𝛼. Plasmid pGFP-HIF-1𝛼 was
transfected into HCT116 and HT29 by Lipofectamine LTX
with PLUS reagent (Invitrogen). After CBF treatment in
transfected cells, the expression level of GFP was measured
by POLARstar Omega.
2.11. Xenograft Establishment and Data Collection. To estab-
lish mouse models, 21 female BALB/c nude mice (aged 8
weeks and weighing 16–18 g) were subcutaneously injected
with 5 × 106 HCT116 cells. They were divided equally into
three groups: intratumoural (i.t.) injection, intraperitoneal
(i.p.) injection, and control group.The treatmentwas initiated
with average tumour size of each group of about 320mm3.
0.2mg/mL injection solution was made by dissolving 10mg
of CBF in 8% of absolute ethanol and 10% of propylene glycol
solution. The daily dose given to i.t. and i.p. groups was
1.5mg/kg. When the tumour grew to 1000mm3, the mouse
was sacrificed. Tumour tissue specimens were collected for
subsequent RNA, protein, and immunohistochemistry anal-
ysis. All experiments involving animals were approved by
Griffith University (AEC No. MSC/01/08).
2.12. Statistical Analysis. All results are presented as means
± S.E. A student’s 𝑡 test computation was used to analyse the
data with unequal variance between each group. A 𝑃 < 0.05
was considered significant.
3. Results
3.1. CBF Exhibits Differential Cytotoxicity in a Plethora of
Cancer Cells with Potent Proapoptotic Effects on Colon Cancer.
When colon, lung, skin, prostate, and breast cancer cell lines
were treated with CBF (Figure 1(a)), significant decreases of
cell viability were showed in all the cancer cell lines in a dose-
dependent manner. The EC
50
values varied from cell line
to cell line indicating CBF’s differential cytotoxicity. When
compared with other cancer cell lines, colon cancer cell lines
HCT116 and HT29 were the most sensitive to CBF. Annexin
V/PI staining assays in CBF-treated HCT116 and HT29 cell
lines showed that both proportions of apoptotic cells (lower
right) and dying cells stained with both dyes (upper right)
were significantly increased after CBF exposure (Figure 1(b)),
only a very small percentage of dead cells stained positive
with PI (upper left). Annexin V binds to the surface of apop-
totic cells, while cellmembrane-impermeant PI binds toDNA
in dead cells. Our result showed a shift of cell population
prone to the left, suggesting thatmost treated cells had under-
gone apoptosis rather than necrosis.
To further verify that the cells died via apoptosis, wemea-
sured the change of mitochondrial transmembrane potential
using a JC-1 dye. The JC-1 dye is aggregated in mitochondrial
matrix and gives out red fluorescence in healthy cells but
turns to green whenmitochondrial electrochemical potential
alters. Therefore, a strong green signal indicates that more
cells are undergoing apoptosis. As shown in Figure 1(c),
mitochondrial transmembrane potential changed in both cell
lines upon CBF treatment. The fractions of green over red
fluorescence were elevated because of an increasing number
of cells undergoing apoptosis after the addition of CBF. In
addition, a study on signalling pathways underlying CBF
cytotoxicity was conducted and ten cellular pathways ranging
from stress, cell cycle to cell death were included. Due to
low transfection efficiency of HT29, only HCT116 cells were
examined by transfecting with specific luciferase reporter
genes of the 10 pathways (Figure 1(d)). The differences of
luciferase expression between treated and control groups
indicated the activation level of the respective signalling path-
way. The activity of HIF-1𝛼 was found to be downregulated
by 2.8-fold between CBF-treated and untreated cells, while
serum response factor (SRF/Elk-1) was upregulated by 2.4-
fold. As such, our laboratory hypothesised that CBF plays
an inhibitory role in HIF-1𝛼 expression but simultaneously
stimulates SRF/Elk-1 mediated pathway as well in HCT116
cells.
3.2. Apoptotic Cell Death in HCT116 Is through Both Caspase-
3-Dependent and -Independent Pathways. To further explore
the mode of cell death, we studied the activation of a
prominentmarker for apoptosis, caspase-3, by using confocal
microscopy (Figure 2(a)). After 24 hours exposure to CBF,
both treated and untreated cells were stained with antiactive
caspase-3 antibodies. The bright green fluorescence of active
caspase-3 was mostly detected in CBF-treated HCT116. Also,
the temporal profile of activation caspase-3 was examined. A
time course study showed that caspase-3/7 levels increased
after 12 hours treatment (Figure 2(b)). Small subunit caspase-
7 and large subunit caspase-3 forming a heterodimer con-
tribute to the execution of apoptosis [25]. The intensity of
active caspase-3/7 in treated cells was about three times as
much as that of untreated cells after 24 hours. Interestingly,
the total mRNA level of caspase-3 firstly decreased at 12 hours
and then increased after 24 hours to the level of control
groups (Figure 2(c)). This indicated that the cytotoxicity
of CBF does not directly affect the transcription level of
caspase-3. However, the level of active caspase-3 protein
was upregulated (Figure 2(d)). Since mitochondrial protein
AIF can lead to caspase-3-independent apoptosis, the role
of AIF was further investigated in CBF-induced apoptosis.
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Figure 1: Cytotoxic effects of CBF in human cancer cell lines. (a) Cytotoxicity assays of CBF. A variety of human cancer cell lines were
exposed to CBF for 24 hours and exhibited a reduction in cell numbers. The EC
50
values were measured by using MTT assays. Results are
means with standard errors from 9 replicates. (b) Annexin V/PI analysis by flow cytometry. HCT116 and HT29 cells were treated with 0 or
1 𝜇MCBF for 24 hours and stained with Annexin V/PI dyes. The lower right percentage indicated the apoptotic cells stained with Annexin V
and represented a significant increment after exposure to CBF, as well as the proportion of dying cells stained with both dyes (upper right).
No elevation in PI stained cells (upper left) was observed and a reduction was in living cell number (lower left) after CBF treatment. (c) The
occurrence of mitochondrial permeabilisation in CBF-induced cell death. Untreated and CBF-treated HCT116 and HT29 cells were stained
with JC-1 dye, which shows red in living cells and green in dying cells. The fraction (green/red) between treated and untreated cells indicated
the change of mitochondrial potential transition. Results are means with standard errors from 3 replicates. (d) Deregulation in cytotoxicity
signaling multipathway arrays after CBF treatment. The most significant change is in HIF-1𝛼-regulated pathway, in which HIF-1𝛼 level was
2.8 times as low as the untreated cells. On the other hand, the most upregulation occurred in the MAPK/ERK pathway, where the expression
of SRF/Elk-1 increased by 2.4 times.The logarithm of untreated cell luciferase intensity was set to baseline. p53, pathway of p53/DNA damage;
HIF-1, pathway of hypoxia; NF𝜅B, pathway of NF𝜅B; GR, pathway of glucocorticoid receptor; E2F, pathway of cell cycle/pRb-E2F; SRF/Elk-
1, pathway of MAPK/ERK; AP-1, pathway of MAPK/JNK; NFAT, pathway of PKC/Ca2+; SMAD2/SMAD3/SMAD4, pathway of TGF𝛽; and
Myc/Max, pathway of Myc/Max. Results are means with standard errors from 4 replicates.
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Figure 2: CBF-induced apoptosis is both caspase-3 dependent and independent in HCT116 cells. (a) Expression of active caspase-3 detected
by confocalmicroscopy. HCT116 cells were treatedwith 0 or 1𝜇MofCBF for 24 hours and analysed by immunofluorescence.The expression of
active caspase-3 (green fluorescence) was only observed in treated HCT116. Cell nuclei were stained with DAPI (blue fluorescence). Scale bars
equal 10𝜇m. (b) Detection of caspase-3/7 activity via a time course. A significant increase of caspase-3/7 activity was found after 24-hour-CBF
exposure (𝑁 = 9, ∗𝑃 < 0.05 compared to the control group). (c) RT-PCR of caspase-3 and AIF. While caspase-3 transcript levels decreased at
initial 12 hours but increased at 24 hours, the mRNA level of AIF decreased by time. Results are means with standard errors from 3 replicates.
(d) Protein expression of active caspase-3 and cleaved AIF after CBF exposure. After 24-hour treatment, both effective caspase-3 (17 kDa) and
dissociated AIF (57 kDa) were produced. (e) Enhancement of cancer cell survival by NAC. The mixture of different concentrations of CBF
and NAC partially inhibited cell death (𝑁 = 9, ∗𝑃 < 0.05).
Our results showed that the mRNA level of AIF kept decreas-
ing after CBF exposure (Figure 2(c)). This indicated that the
transcription of AIF was inhibited, thereby resulting in the
low expression level of total AIF (Figure 2(d)).The amount of
mitochondrial-anchored AIF (67 kDa) was also diminished
significantly, leaving the cleaved free AIF (57 kDa).Moreover,
the addition of antioxidant NAC efficiently enhanced the
resistance of HCT116 to CBF (Figure 2(e)). NAC inhibits the
production of reactive oxygen species (ROS) and decreases
mitochondrial potential changes, leading to reduction of AIF
release. The cell viability assays showed that NAC partially
elevated the survival of CBF-treated HCT116. This is most
likely due to NAC preventing CBF-treated cells from mito-
chondrial permeabilisation and subsequent AIF-mediated
caspase-3-independent apoptosis.
3.3. Apoptotic Cell Death in HT29 Is through Caspase-3-Inde-
pendent Pathway Only. In contrast to HCT116, the activity
of caspase-3/7 was reduced in HT29 cells after 24 hours of
CBF exposure (Figure 3(a)). No active caspase-3 or cytosolic
AIF (57 kDa) was detected even after 48 hours of CBF
treatment (Figure 3(b)). Consistently, no significant shift of
AIF intracellular distribution between 48-hour-treated and
untreated HT29 cells was observed by confocal microscopy
(Figure 3(c)). Analysis of mRNA level showed no apparent
involvement of CBF in transcription of caspase-3 and AIF
(Figure 3(d)). The mRNA level of caspase-3 increased at
12 hours but eventually decreased after 24 hours, while
AIF mRNA level was slightly reduced after CBF addition.
Furthermore, in contrast to the case of HCT116, NAC was
unable to counter the CBF cytotoxicity of HT29 cells until the
CBF concentration of up to 10mM (Figure 3(e)), indicating
that ROS accumulation in mitochondria is not a direct
cause of the cell death. In addition, the high sensitivity of
untreated HT29 to NAC alone was most likely to result
from suppression of c-Src phosphorylation [26].Themassive
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Figure 3: CBF-induced HT29 apoptosis is neither caspase-3 nor AIF dependent. (a) The inhibition of caspase-3/7 activity in CBF-treated
HT29 cells. Treated and untreated cells were lysed and the assessment of caspase-3 luciferase intensity showed that caspase-3/7 activity was
significantly downregulated after 24-hour treatment (𝑁 = 9, ∗𝑃 < 0.05). (b) No expression of active caspase-3 and cleaved AIF. After 48-hour
treatment, only mitochondria-localised AIF (67 kDa) was detected by immunoblotting. (c) No obvious shift in AIF distribution between
treated and control groups. After CBF addition of 24 hours, red fluorescence representing AIF expression exhibited no enhancement of AIF
nuclear translocation. Cell nuclei were stained with DAPI (blue fluorescence). Scale bars equal 10𝜇m. (d) RT-PCR of AIF and caspase-3.
mRNA level of caspase-3 firstly increased after 12 hours and then decreased at 24 hours, but there was no significant change in AIF mRNA
level. Results are means with standard errors from 3 replicates. (e) Failure of cancer cell rescue by NAC. The mixture of CBF and NAC was
unable to prevent cells from CBF-induced apoptosis (𝑁 = 9, ∗𝑃 < 0.05).
blockade of c-Src kinases by NAC arrests HT29 cells in G1
phase of cell cycle.
3.4. The Inhibition of HIF-1𝛼 Protein by CBF Is Not due to the
Suppression of RNA Transcription. Unlike the result from
multipathway reporter arrays, HIF-1𝛼 mRNA levels of CBF-
treated HCT116 and HT29 cells noticeably increased during
48 hours under hypoxic and normoxic conditions, compared
with that of controls (Figures 4(a) and 4(b)). This result
suggested that transcription of HIF-1𝛼 mRNA is relevant
to CBF exposure, and CBF particularly enhances HIF-1𝛼
transcription under 1% oxygen atmosphere. However, further
investigation on HIF-1𝛼 protein showed that the expression
of HIF-1𝛼 protein was inhibited by CBF (Figure 4(c)). The
most significant inhibition was at 24 hours time point in
both cancer cell lines. Another method to assess the level of
HIF-1𝛼 protein was by measuring the expression of a GFP-
HIF-1𝛼 fusion protein in CBF-treated HCT116 and HT29
cells. Transfected cells were exposed to CBF for 24 hours
under 1% of oxygen. GFP intensity under 20% of oxygen
was also measured and predictably at low levels. As shown
in Figure 4(d), the expression level of GFP in CBF-treated
HCT116 and HT29 cells was significantly reduced.
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Figure 4: CBF affects HIF-1𝛼 transcription and protein expression. (a) Elevation of HIF-1𝛼 transcription level by CBF in HCT116 cells.
Compared with that in normal atmosphere, the level of HIF-1𝛼 mRNA doubled when HCT116 cells were in lack of oxygen. (b) Elevation
of HIF-1𝛼 transcription level by CBF in HT29 cells. Dramatic upregulation of HIF-1𝛼 mRNA was only from 8 to 18 hour time points,
followed by a sharp fall at 24 hours.The patterns of HIF-1𝛼 transcription of HT29 between 1% and 20% were similar. (c) Inhibition of HIF-1𝛼
protein expression. Under hypoxic (100𝜇MCoCl
2
) conditions, HIF-1𝛼 protein expression was suppressed by CBF at different time points. (d)
Inhibition of GFP fused HIF-1𝛼 expression. Plasmid pGFP-HIF-1𝛼 was transfected into HCT116 and HT29 cells, followed by a 24-hour-CBF
treatment under 1% or 20% oxygen. Compared with the control groups, 1𝜇M of CBF exposure effectively inhibited the expression of GFP
under hypoxic conditions (𝑁 = 6, ∗𝑃 < 0.05).
3.5. CBF Affects the Expression of HIF-1𝛼 in HCT116 Tumour
Bearing Xenografts. In an effort to define the anticancer
function of CBF in animal models, we established HCT116
implanted xenografts, and CBF treatment (1.5mg/kg) was
given daily by i.t. and i.p. injection.The lowest tumour growth
rate was in i.p. group (Figure 5(a)). All mice from groups
of control and i.t. injection were sacrificed on day 13 and
day 15, respectively. The mRNA analysis of tumour tissues
showed that HIF-1𝛼 mRNA level was dramatically elevated
in i.p. group (Figure 5(b)). This finding is consistent with
the increase of HIF-1𝛼 mRNA level in cell line experiments.
More significantly, the fluorescent images frommouse tissues
exhibited a clear inhibition in nuclear translocation of HIF-
1𝛼 in i.t. group (Figure 5(c)). This shift was also found in
a number of cells in i.p. group. Compared with treatment
groups, the HIF-1𝛼 import was apparent in the control group.
4. Discussion
Natural medicine, like Chansu, has been widely used in
the clinic for human patients in China, Japan, and other
Asian countries as an anaesthetic, antibiotic, anticancer
and cardiotonic medication. However, like many of these
natural therapies, their molecular mechanisms have not been
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Figure 5: Analysis of CBF treatment in HCT116 implanted mouse models and tumour tissue samples. (a) Tumour size versus CBF treatment.
The lowest tumour growth rate was found in i.p. group during CBF treatment. (b) Analysis of HIF-1𝛼mRNA level in tumour tissues. There
was a significant upregulated HIF-1𝛼 level in i.p. group. Results are means with standard errors from 4 replicates. (c) Inhibition of HIF-1𝛼
nuclear translocation in the i.t. sample. CBF strongly inhibited HIF-1𝛼 nuclear accumulation in the tumour of xenografts implanted with
HCT116 cells. Scale bars equal 10𝜇m. White arrows: HIF-1𝛼 in the cytosol.
elucidated. As such the claims of effectiveness have not been
fully tested. Recently, an increasing number of in vitro studies
have revealed the proapoptotic function of Chansu and its
components in cancer cells [14, 16, 17]. CBF is one of the
major bufadienolide compounds and a variety of molecular
mechanisms have been proposed, that is, inhibition of nuclear
factor Kappa B (NF𝜅B) activation [18] and attenuation of
phosphorylation in ERK-related pathway [27]. According to
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the classification of bufadienolides, CBF is also a type of CGs.
One distinct advantage of CG compounds as anticancer
agents is that they have high efficacy and safety profiles [24,
28, 29]. This is consistent with the finding of our laboratory
that the human head and neck cancer cell line HN5 was
drastically resistant to CBF-induce cell death (EC
50
> 6.5 𝜇M,
Li andWei, publication in preparation).We showed that CBF
inhibitory effects on cancer cell growth were variable, with
different EC
50
values among different cell lines. The lowest
EC
50
exhibited at 86 nM in HCT116 and the most resistance
was in A431 at approximately 6 𝜇M of CBF. Cell viability
assays showed that colon cancer cell lines exhibited an overall
higher cell death efficacy of CBF than that of breast, skin, and
lung cancer cell lines. This high sensitivity to colon cancer
cells is consistent with the previous finding of Sakai et al. [30],
who demonstrated that ouabain has a preferential binding to
alpha 3 (𝛼3) subunit of Na+/K+-ATPase. They showed that
there was an elevation of 𝛼3 subunit expression in colorectal
cancer tissues, as well as in the HT29 cell line. Therefore,
it is possible that CBF selectively binds to 𝛼3 subunits and
gives rise to a high inhibitory effect in colon cancer cell lines.
Furthermore, we found that even within two highly sensitive
cancer cell lines, HCT116 and HT29 cells underwent very
distinct apoptotic processes.The classic caspase-3-dependent
apoptosis was only detected in CBF-treated HCT116 but not
in CBF-treated HT29.
Recent reports suggest that another key feature of the
CG-related proapoptotic mechanism is mitochondrial injury
[31]. Indeed the results of this study demonstrated that
the change of mitochondrial potential is involved in CBF-
induced cell death and linked this change to AIF-mediated
apoptosis. The release of AIF can be due to a sustained
increase of intracellular Ca2+ level, which causes calpain
activation [32]. Calpain is a calcium-dependent protease and
activated calpain cleaves AIF in mitochondria [33]. Yeh et al.
revealed an elevation of cytosolic Ca2+ in prostate cancer cell
lines after CBF treatment [20]. This mechanism could also
operate in AIF-regulated apoptosis in HCT116 cells. Apart
from calpain cleavage, a high intracellular Ca2+ concentration
also leads to the production of ROS in mitochondria [34].
Such enhancement of ROS by CBF is a likely explanation for
the disruption ofmitochondria in our experiments. Although
the expression of dissociated AIF was only observed in
CBF-treated HCT116 cells, increased mitochondrial per-
meabilisation was observed in both cell lines. Moreover,
Newman et al. (2006) found that NAC prevents oleandrin
(a type of CG) induced mitochondrial condensation in
malignant melanoma by inhibition of ROS production [31].
The addition of NAC to HCT116 cells also significantly
reduced CBF-induced apoptosis in our experiments. This
further indicated a likely correlation between mitochondrial
disruption and CBF cytotoxicity. Intriguingly, proapoptotic
Bax expression was suppressed after CBF treatment in both
colon cancer cells (see Supplementary Figure 1 available
online at http://dx.doi.org/10.1155/2013/849054). After all,
CBF did elicit apoptosis in HT29, but the apoptotic pathways
remain independent of the activity of caspase-3 and AIF,
suggesting other apoptotic mechanisms could be involved
in CBF anti-cancer capacity. A possibility could be through
necroptosis, which is a necrotic mechanism crosslinking to
apoptosis [35]. Necroptosis depends on the activation of
receptor-interacting protein kinases 1 (RIPK1) and RIPK3,
which leads to mitochondrial disrupt due to several factors,
such as ATP depletion, ROS accumulation and elevation of
Ca2+ [36]. Another important characteristic of necroptosis
is suppression of caspase-8, a precursor of caspase-3/7 [37].
Thus, necroptosis could be a rational explanation for mito-
chondrial injury and caspase-3 deactivation in CBF-induced
cell death in HT29 cells. In addition, AIF possesses a capacity
to regulate caspase-independent necroptosis, but it is not
essential [38]. Our results implied no involvement of AIF
activity in CBF-treated HT29 cells.
Furthermore, the assessment of the 10-pathway reporter
arrays suggested a multifactorial network involved in CBF-
mediated apoptosis. Overall, the most significant inhibi-
tion was in HIF-1𝛼-regulated pathway. The expression of
HIF-1𝛼 intimately corresponds to changes in oxygen levels
[39]. During oxygen deprivation, degradation of HIF-1𝛼 is
inhibited, permitting HIF-1𝛼 to enter the nucleus, where it
binds to aryl hydrocarbon receptor nuclear translocator and
initiates the transcription of hypoxia-responsive genes. HIF-
1𝛼 mediates the transcription of several oncogenic genes,
especially vascular endothelial growth factor (VEGF) and
thereby promotes cell proliferation [40]. In relation to the
inhibition of HIF-1𝛼, although there is no direct relationship
established betweenHIF-1𝛼 andCBF, several previous studies
showed that digoxin and other cardiac glycosides inhibit
HIF-1𝛼 synthesis to retard tumour growth [41, 42]. Thus,
there is a possibility that the digoxin-like molecule CBF
reduces HIF-1𝛼 levels in colon cancer cell lines as well.
Indeed our findings showed that HIF-1𝛼 protein expression
was suppressed by CBF as early as 6 hours after treatment
in both colon cancer cell lines, regardless of the elevation
of mRNA transcript. Another result from the estimation
of GFP-HIF-1𝛼 expression confirmed further the inhibition
of exogenous HIF-1𝛼 expression in the presence of CBF.
Moreover, HIF-1𝛼 was found to localise in the cytosol of
mouse tumour cells and did not accumulate in the nucleus.
Although there is little information in hand to elucidate the
mechanism involved in CBF function in tumour tissues, an
inhibitory role was still revealed in the blockade of HIF-1𝛼
import in CBF-treated xenografts implanted with HCT116.
Apart from the protein downregulation, the increase of HIF-
1𝛼mRNA level might be due to the activation ofMAPK/ERK
pathway, the second most affected pathway shown in 10-
pathway reporter assays. A number of previous studies have
revealed that stimulation of the MAPK pathway enhances
HIF-1𝛼 transcriptional activity [43].Thus, taken together our
findings suggest that the hypoxia-regulated cellular pathway
is involved in CBF-driven cell death.
5. Conclusion
CBF inhibited cancer cell growth by induction of apoptosis
through different pathways.The significant inhibition ofHIF-
1𝛼 nuclear translocation strongly suggested the involvement
of hypoxia pathway in vivo in animal models. Taken together,
our findings showed that CBF is a highly potent inhibitor
10 Evidence-Based Complementary and Alternative Medicine
of cancer growth, has high efficacy and safety profiles, and
has the potential to be developed as an effective anticancer
chemotherapeutic agent.
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